WO2024050031A3 - Novel camptothecin derivatves as antibody-drug conjugates (adc) payloads - Google Patents

Novel camptothecin derivatves as antibody-drug conjugates (adc) payloads Download PDF

Info

Publication number
WO2024050031A3
WO2024050031A3 PCT/US2023/031737 US2023031737W WO2024050031A3 WO 2024050031 A3 WO2024050031 A3 WO 2024050031A3 US 2023031737 W US2023031737 W US 2023031737W WO 2024050031 A3 WO2024050031 A3 WO 2024050031A3
Authority
WO
WIPO (PCT)
Prior art keywords
payloads
antibody
drug conjugates
derivatves
adc
Prior art date
Application number
PCT/US2023/031737
Other languages
French (fr)
Other versions
WO2024050031A2 (en
Inventor
Dinnguo LIU
Haifeng Bao
Yuan WEI
Haihong Zhong
Shen LIU
Lijin CAO
Original Assignee
Bionecure Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionecure Therapeutics Inc filed Critical Bionecure Therapeutics Inc
Publication of WO2024050031A2 publication Critical patent/WO2024050031A2/en
Publication of WO2024050031A3 publication Critical patent/WO2024050031A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention describes novel camptothecin derivatives and methods for preparing camptothecin derivative payloads bearing a linker with a functional group that can be used for conjugation to cell binding agents to generate cytotoxic drug conjugates. The present invention further relates to antibody drug conjugates made with camptothecin derivative payloads bearing a linker moiety conjugated to tumor associated antigen (TAA) antibody, preparation methods, pharmaceutical compositions and uses thereof for the treatment of cancer. Methods relating to the use of the novel ADCs to treat antigen positive cells in cancers and immunological disorders are also provided herein.
PCT/US2023/031737 2022-08-31 2023-08-31 Novel camptothecin derivatves as antibody-drug conjugates (adc) payloads WO2024050031A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263402603P 2022-08-31 2022-08-31
US63/402,603 2022-08-31

Publications (2)

Publication Number Publication Date
WO2024050031A2 WO2024050031A2 (en) 2024-03-07
WO2024050031A3 true WO2024050031A3 (en) 2024-04-25

Family

ID=90098622

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/031737 WO2024050031A2 (en) 2022-08-31 2023-08-31 Novel camptothecin derivatves as antibody-drug conjugates (adc) payloads

Country Status (1)

Country Link
WO (1) WO2024050031A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160297890A1 (en) * 2013-12-25 2016-10-13 Daiichi Sankyo Company, Limited Anti-trop2 antibody-drug conjugate
US20210077482A1 (en) * 2019-04-26 2021-03-18 Immunogen, Inc. Camptothecin derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160297890A1 (en) * 2013-12-25 2016-10-13 Daiichi Sankyo Company, Limited Anti-trop2 antibody-drug conjugate
US20210077482A1 (en) * 2019-04-26 2021-03-18 Immunogen, Inc. Camptothecin derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LI ET AL.: "Synthesis and Evaluation of Camptothecin Antibody-Drug Conjugates", ACS MED. CHEM. LETT., vol. 10, 2019, pages 1386 - 1392, XP055758576, DOI: 10.1021/acsmedchemlett.9b00301 *

Also Published As

Publication number Publication date
WO2024050031A2 (en) 2024-03-07

Similar Documents

Publication Publication Date Title
WO2020126609A3 (en) Antibody drug conjugates (adc) containing saponin
MX2021015887A (en) A conjugate of a cytotoxic agent to a cell binding molecule with branched linkers.
AU2012257418B2 (en) Bio-orthogonal drug activation
Flygare et al. Antibody‐drug conjugates for the treatment of cancer
CA2076465C (en) Cell binding agent conjugates of analogues and derivatives of cc-1065
WO2004073656A3 (en) Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
WO2022010797A3 (en) Maytansinoids as adc payloads and their use for the treatment of cancer
ES2551233T3 (en) Methods for the preparation of cytotoxic conjugates of maitansinoids and agents that bind to cells
PH12021550692A1 (en) Conjugation linkers containing 2,3-diaminosuccinyl group
MY104944A (en) Anthracycline immunoconjugates having a novel linker and methods for their production
WO2010115629A3 (en) Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy
MX2023001163A (en) Anti-cd79b antibody-drug conjugate, and preparation method therefor and pharmaceutical use thereof.
IN2012DN02780A (en)
TW200500069A (en) Vitamin-receptor binding drug delivery conjugates
JP2018507844A (en) Antibody drug conjugate
Chowdari et al. Uncialamycin as a novel payload for antibody drug conjugate (ADC) based targeted cancer therapy
WO2022093800A3 (en) Carrier particle-drug conjugates, self-immolative linkers, and uses thereof
WO2018078648A4 (en) Gold nanoparticle based formulation for use in cancer therapy
WO2024050031A3 (en) Novel camptothecin derivatves as antibody-drug conjugates (adc) payloads
AU2021284918A1 (en) Therapeutic conjugates
WO2005002516A3 (en) Leukocyte internalized peptide-drug conjugates
WO2023009835A3 (en) Antibody conjugates specific for mucin-1 and methods of use thereof
WO2022180581A3 (en) Anti-her2 antibody-drug conjugates and uses thereof
MX2023008341A (en) Dual-cleavage ester linkers for antibody-drug conjugates.
WO2021261996A3 (en) Hydrazone-based saponin derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23861308

Country of ref document: EP

Kind code of ref document: A2